176 related articles for article (PubMed ID: 24819422)
1. Impact of (18)F-Fluoride PET on Intended Management of Patients with Cancers Other Than Prostate Cancer: Results from the National Oncologic PET Registry.
Hillner BE; Siegel BA; Hanna L; Duan F; Shields AF; Quinn B; Coleman RE
J Nucl Med; 2014 Jul; 55(7):1054-61. PubMed ID: 24819422
[TBL] [Abstract][Full Text] [Related]
2. Impact of 18F-fluoride PET in patients with known prostate cancer: initial results from the National Oncologic PET Registry.
Hillner BE; Siegel BA; Hanna L; Duan F; Shields AF; Coleman RE
J Nucl Med; 2014 Apr; 55(4):574-81. PubMed ID: 24578240
[TBL] [Abstract][Full Text] [Related]
3. Intended Versus Inferred Treatment After
Hillner BE; Hanna L; Makineni R; Duan F; Shields AF; Subramaniam RM; Gareen I; Siegel BA
J Nucl Med; 2018 Mar; 59(3):421-426. PubMed ID: 29191854
[TBL] [Abstract][Full Text] [Related]
4. Hospice Admission and Survival After
Gareen IF; Hillner BE; Hanna L; Makineni R; Duan F; Shields AF; Subramaniam RM; Siegel BA
J Nucl Med; 2018 Mar; 59(3):427-433. PubMed ID: 29284672
[TBL] [Abstract][Full Text] [Related]
5. 18F-fluoride PET used for treatment monitoring of systemic cancer therapy: results from the National Oncologic PET Registry.
Hillner BE; Siegel BA; Hanna L; Duan F; Quinn B; Shields AF
J Nucl Med; 2015 Feb; 56(2):222-8. PubMed ID: 25593113
[TBL] [
